Sec Form 3 Filing - Poetting Sierk @ BioNTech SE - 2026-03-18

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Poetting Sierk 2. Issuer Name and Ticker or Trading Symbol BioNTech SE [ BNTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Operating Officer (Last) (First) (Middle) C/O BIONTECH SE, AN DER GOLDGRUBE 12 3. Date of Earliest Transaction (MM/DD/YY) 03/18/2026 (Street) MAINZD-55131 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares 449,387 I See Footnote ( 1 ) Ordinary Shares 141,514 D Ordinary Shares 1,638 I See Footnote ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Option (right to buy) $ 113.94 ( 5 ) 05/22/2027( 3 ) 05/22/2033 Ordinary Shares ( 4 ) 18,416 D Option (right to buy) ( 5 ) ( 6 ) 08/26/2028( 3 ) 08/26/2034 Ordinary Shares ( 4 ) 25,459 D Option (right to buy) ( 5 ) ( 7 ) 05/28/2029( 3 ) 05/28/2035 Ordinary Shares ( 4 ) 8,838 D Phantom Option $ 185.23 ( 5 ) 05/12/2025( 3 ) 05/12/2031 Ordinary Shares ( 8 ) 7,112 D Phantom Option $ 152.1 ( 5 ) 05/31/2026( 3 ) 05/31/2032 Ordinary Shares ( 8 ) 14,664 D Performance Share Unit $ 0 05/27/2029( 9 ) 05/27/2035 Ordinary Shares ( 9 ) 11,047 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Poetting Sierk C/O BIONTECH SE AN DER GOLDGRUBE 12 MAINZD-55131 Chief Operating Officer Signatures /s/ Humza Bokhari, Attorney-in-Fact 03/18/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The ordinary shares are held by Tofino GmbH. The Reporting Person is the sole shareholder of Tofino GmbH and may be deemed to beneficially own the ordinary shares held by Tofino GmbH. ( 2 )The ordinary shares are held by the Reporting Person's immediate family. The Reporting Person disclaims beneficial ownership of the ordinary shares noted herein except to the extent of his pecuniary interest therein. ( 3 )The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions. ( 4 )The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board. ( 5 )Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price. ( 6 )The exercise price of this option is EUR 75.91. ( 7 )The exercise price of this option is EUR 93.35. ( 8 )Each phantom option represents the right to receive a cash payment equal to the difference between an exercise closing price (average closing price of an ADS over the last ten trading days preceding the exercise date) and the exercise price. ( 9 )Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

Remarks: Exhibit List - Exhibit 24 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.